Stem Cell Transplant & Cellular Therapy

Transplant and CAR-T are different treatments

A blood stem cell transplant helps rebuild the body’s blood production after intensive treatment. Blood-forming stem cells normally live in the bone marrow, the soft tissue inside bones. They make red blood cells that carry oxygen, white blood cells that fight infection and platelets that help stop bleeding.

Chimeric antigen receptor T-cell (CAR-T) therapy uses a different kind of cell. T cells are immune cells that help defend the body. In established CAR-T treatments, a person’s own T cells are collected and changed in a laboratory so they can recognise a particular target on cancer cells. They are then returned through a vein.

These treatments have different purposes and are not interchangeable. Transplants are used for selected leukaemias, lymphomas, myeloma and other blood disorders, and occasionally other cancers. CAR-T is an option for particular blood cancers, including some lymphomas, acute lymphoblastic leukaemia and myeloma. The exact diagnosis, previous treatment, available product and individual eligibility matter.

For some people the aim is cure; for others it is a longer period with the cancer controlled. Neither treatment guarantees that the cancer will go away or stay away. Your team should explain the goal and likely benefit for your particular disease.

Hearing that you may need a transplant or cellular therapy can feel overwhelming. Start with one question: “Why are you considering this for me?” Ask the team to explain the expected benefit, alternatives and the next step before trying to absorb the whole pathway.

Autologous and allogeneic transplant

Autologous: using your own cells

An autologous transplant uses your own blood stem cells. They are collected and stored before high-dose chemotherapy—strong doses of medicines that kill cancer cells—then returned afterwards to restore blood production. In this approach, the intensive cancer treatment does the main work against the cancer; the returned cells help the marrow recover. It is used, for example, in selected myeloma and lymphoma treatment plans.

Allogeneic: using a donor’s cells

An allogeneic transplant uses blood stem cells from another person. Alongside replacing blood production, the donor’s immune cells can attack remaining cancer cells. This is called a graft-versus-leukaemia or graft-versus-tumour effect. The donor immune system can also attack healthy tissues, so additional medicines and monitoring are needed.

Donor matching uses human leukocyte antigen (HLA) markers—proteins that help the immune system recognise cells. This is different from matching the blood group. A donor may be a relative or an unrelated volunteer; a partly matched relative or cord blood may be considered in some situations. A specialist team assesses the safest suitable option.

“Bone marrow transplant”, sometimes shortened to BMT, is a familiar term, but many transplants use stem cells collected from the bloodstream. Bone marrow and donated umbilical cord blood are other sources. The name describes the cells and their source; it does not mean that bone is being transplanted.

Planning your venous access

Venous access means a way to give treatment through a vein. A central line is a thin tube whose tip sits in a large vein near the heart. It can be used for medicines, fluids, blood transfusions and the stem cell infusion. Some lines can also be used for cell collection.

The team chooses the device for your treatment plan. A tunnelled line runs under the skin before entering the vein; other options include an implanted port or a peripherally inserted central catheter (PICC), which enters through an arm vein. The same device is not right for everyone.

Before going home, ask who will look after the line, how dressings and flushing will be arranged, and which changes need urgent contact. Report redness, pain, swelling, leakage or fever promptly. If handling the line worries you, ask for a demonstration and support.

The transplant pathway

Assessment and preparation

The team reviews your diagnosis, response to earlier treatment, general fitness and other health conditions. Tests may assess blood counts, infections, heart, lungs, kidneys and liver. Age is considered alongside these findings. Ask what the assessment means for your own balance of benefit and risk.

Discuss fertility before treatment, because the ability to have children may be affected. Review medicines and supplements, dental or infection concerns and any support you need at home. A caregiver can join these conversations. Ask for a written schedule and a number for urgent advice.

From cell collection to blood-count recovery

1. Collecting cells. For an autologous transplant, medicines help move stem cells from marrow into the blood. A machine collects them and returns the remaining blood; this is called apheresis. The cells are checked and stored. For a donor transplant, the collection method is planned with the donor team.
2. Conditioning. Chemotherapy, sometimes with radiotherapy (treatment using high-energy radiation), prepares the body for the transplant. The treatment and its intensity depend on the disease and transplant type. Some donor transplants use reduced-intensity conditioning, which still needs careful monitoring.
3. The infusion. The cells are given through a vein, usually through a central line. This is an infusion, similar to a blood transfusion, rather than an operation to put cells into the bones. Staff monitor you during the infusion. This day is often called day zero.
4. Engraftment. The cells settle in the marrow and begin making blood cells. This is called engraftment. While counts are low, you may need transfusions, infection treatment or prevention, and help with eating and drinking.

The timetable varies. Ask what needs to happen before discharge and how often you will return afterwards. A longer stay or a delay in the schedule does not by itself tell you whether the cancer treatment has worked.

Transplant risks and recovery

Early effects can include mouth soreness, nausea, diarrhoea, hair loss and marked tiredness. Low white blood cells increase infection risk; low platelets increase bleeding risk. Tell the team about symptoms early so that they can assess the cause and arrange treatment or help with eating and drinking.

After an allogeneic transplant, graft-versus-host disease (GVHD) can occur when donor immune cells attack healthy tissues. It may affect the skin, gut, liver or other organs, and can develop early or later. Medicines help prevent or treat it. Report changes such as a new rash, persistent diarrhoea, yellowing of the eyes or new breathing problems.

Other important risks include the transplanted cells not establishing normal blood production, damage to organs and the cancer returning. Some complications can be life-threatening. Your team should explain which risks are most relevant to you, how they will be monitored and how they compare with the alternatives.

Recovery continues after you leave hospital. Blood counts can improve before the immune system has fully recovered. Follow the team’s instructions about medicines, food safety, infection precautions and vaccinations. Do not stop medicines that suppress the immune system after a donor transplant without the team’s advice.

Follow-up also looks for late effects, including changes in fertility, hormones or organ health, and other cancers. Keep a treatment summary. Returning to work, study and activity is gradual and individual; needing help for longer than expected is a reason to discuss support, not something to feel guilty about.

The CAR-T pathway

CAR-T treatment begins with a specialist assessment. The team checks whether your cancer and previous treatments meet the requirements for a particular product, and whether your health allows the treatment and monitoring. Suitability and access must be confirmed for the country, product and treating centre.

1. Collecting T cells. Blood passes through a machine that collects white blood cells and returns the rest. This is called leukapheresis. The team advises which medicines need adjusting beforehand; do not change them yourself.
2. Manufacturing. The cells go to a specialist laboratory to be modified, multiplied and checked. This can take several weeks. The team may recommend treatment to control the cancer while you wait, called bridging treatment.
3. Preparing for infusion. A short course of chemotherapy reduces existing immune cells to help the CAR-T cells work. This is called lymphodepleting chemotherapy. Tests and assessment are repeated before proceeding.
4. Infusion and close observation. The CAR-T cells are given through a vein as an infusion. The infusion is one part of a longer course of care: monitoring for reactions and supporting recovery remain essential afterwards.

Occasionally the cells cannot be manufactured successfully, the cancer changes or someone becomes too unwell to proceed. Ask about the backup plan before collection. Being referred or having cells collected does not guarantee that an infusion will follow.

Plan for a caregiver, transport and the required period near the treating centre. Ask which appointments involve admission and which are outpatient visits. You do not have to work out these arrangements alone; tell the team early if they are difficult to organise.

CAR-T monitoring

CAR-T cells can trigger cytokine release syndrome (CRS), an inflammatory reaction caused by immune signals released during treatment. Signs can include fever, low blood pressure and difficulty breathing. Severity varies, and some people need intensive care. Fever can also be an infection, so it needs assessment rather than guessing the cause.

Effects on the nervous system are called immune effector cell-associated neurotoxicity syndrome (ICANS). New confusion, trouble speaking or writing, unusual sleepiness, tremor or seizures need urgent attention. Staff may ask simple questions or check handwriting as part of monitoring. Caregivers should report changes they notice.

Low blood counts and infections can continue after the initial monitoring period. Some treatments also reduce cells that make antibodies—immune proteins that help fight infection—weakening infection protection. Follow-up may include blood tests, medicines to prevent infection, a vaccination plan and, for selected people, infusions of antibodies to help protect against infection.

Before discharge, confirm how long you must stay near the centre, how long a caregiver must be with you, and when driving or other activities can resume. These instructions differ by product and programme; use your own team’s written advice.

Long-term follow-up checks the cancer response, ongoing side effects and general health. New cancers, including cancers involving T cells, have been reported after some CAR-T treatments, so ongoing monitoring matters. Your team can explain what is known about this risk and how it compares with the expected benefit in your situation.

Fatigue (persistent tiredness), appetite changes and worry may continue after the busiest part of treatment. Tell the team what is making everyday life difficult. Ask for a clear plan for recovery, emotional support and who will coordinate care with your usual doctor.

CTI doctors for haemato-oncology care

Haemato-oncology is the care of blood cancers. Your consultation can help clarify the diagnosis, whether specialist transplant or cellular-therapy assessment is appropriate, and what information is needed next. Bring your questions as well as your reports.

Dr Prathyush V

Senior Consultant – Medical Oncology & Haemato-Oncology

Dr Darshan R S

Consultant – Medical Oncology & Haemato-Oncology

Where to get care

Contact CTI to discuss assessment and the appropriate specialist team. Confirm where the proposed treatment, cell collection and follow-up would take place before travelling. The exact procedure, product and arrangements depend on clinical eligibility and the centre’s facilities.

Bannerghatta Road

Apollo Hospitals
Bengaluru

Sarjapur

Apollo Hospitals
Bengaluru

Questions to discuss